Media coverage about Atossa Genetics (NASDAQ:ATOS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Atossa Genetics earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.843359777282 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern’s analysis:

Shares of Atossa Genetics (NASDAQ ATOS) traded down 3.9726% during trading on Tuesday, reaching $0.3505. 42,927 shares of the company were exchanged. Atossa Genetics has a one year low of $0.32 and a one year high of $4.05. The company has a 50 day moving average price of $0.41 and a 200-day moving average price of $0.80. The stock’s market capitalization is $2.60 million.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.20. Equities analysts predict that Atossa Genetics will post ($3.57) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Atossa Genetics (ATOS) Stock Price” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at

About Atossa Genetics

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

Insider Buying and Selling by Quarter for Atossa Genetics (NASDAQ:ATOS)

Receive News & Stock Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related stocks with our FREE daily email newsletter.